BR112012001900A2 - otamixabano para tratamento de pacientes idosos com insuficiência renal e infarto do miocárdio sem elevação do st - Google Patents

otamixabano para tratamento de pacientes idosos com insuficiência renal e infarto do miocárdio sem elevação do st

Info

Publication number
BR112012001900A2
BR112012001900A2 BR112012001900A BR112012001900A BR112012001900A2 BR 112012001900 A2 BR112012001900 A2 BR 112012001900A2 BR 112012001900 A BR112012001900 A BR 112012001900A BR 112012001900 A BR112012001900 A BR 112012001900A BR 112012001900 A2 BR112012001900 A2 BR 112012001900A2
Authority
BR
Brazil
Prior art keywords
otamixaban
elevating
treatment
myocardial infarction
renal failure
Prior art date
Application number
BR112012001900A
Other languages
English (en)
Inventor
Angèle Moryusef
Christophe Gaudin
Jens Stechl
Pascale Ythier-Moury
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of BR112012001900A2 publication Critical patent/BR112012001900A2/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/10Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms
    • C07D211/12Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms with only hydrogen atoms attached to the ring nitrogen atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4409Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
BR112012001900A 2009-07-29 2010-07-22 otamixabano para tratamento de pacientes idosos com insuficiência renal e infarto do miocárdio sem elevação do st BR112012001900A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP09290601 2009-07-29
EP10305192 2010-02-26
PCT/EP2010/060615 WO2011012527A1 (en) 2009-07-29 2010-07-22 Otamixaban for treatment of elderly and renal impaired non-st elevation myocardial infarction patients

Publications (1)

Publication Number Publication Date
BR112012001900A2 true BR112012001900A2 (pt) 2016-03-15

Family

ID=42542846

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012001900A BR112012001900A2 (pt) 2009-07-29 2010-07-22 otamixabano para tratamento de pacientes idosos com insuficiência renal e infarto do miocárdio sem elevação do st

Country Status (25)

Country Link
US (1) US9492437B2 (pt)
EP (1) EP2459193A1 (pt)
JP (1) JP2013500298A (pt)
KR (1) KR20120038982A (pt)
CN (1) CN102470128A (pt)
AR (1) AR077427A1 (pt)
AU (1) AU2010277725B2 (pt)
BR (1) BR112012001900A2 (pt)
CA (1) CA2766533A1 (pt)
CL (1) CL2012000196A1 (pt)
CO (1) CO6491041A2 (pt)
CR (1) CR20110674A (pt)
DO (1) DOP2012000012A (pt)
EC (1) ECSP12011627A (pt)
IL (1) IL217612A (pt)
MA (1) MA33455B1 (pt)
MX (1) MX2012000457A (pt)
NI (1) NI201200008A (pt)
NZ (1) NZ597957A (pt)
PE (1) PE20121401A1 (pt)
RU (1) RU2542455C2 (pt)
SG (1) SG177772A1 (pt)
TW (1) TWI463982B (pt)
UY (1) UY32807A (pt)
WO (1) WO2011012527A1 (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2012234323A1 (en) 2011-03-29 2013-10-17 Sanofi Otamixaban formulations with improved stability
SI2691371T1 (sl) * 2011-03-29 2015-07-31 Sanofi Sol benzojske kisline otamiksabana
TWI551289B (zh) * 2011-03-29 2016-10-01 賽諾菲公司 具有改良之安定性之奧米沙班調配物
EA201590473A1 (ru) * 2012-08-31 2015-06-30 Санофи Отамиксабан для применения в лечении острого коронарного синдрома без подъема st у пациентов, которым планируется проведение аортокоронарного шунтирования

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RO117913B1 (ro) * 1996-01-02 2002-09-30 Aventis Pharmaceuticals Inc. Derivaţi de n-[(amino-(imino)metil)fenil]propil amide substituite, compoziţie farmaceutică care îi conţine şi metodă de tratament
RU2225617C1 (ru) * 2002-12-16 2004-03-10 Научно-исследовательский институт кардиологии Томского научного центра СО РАМН Способ определения дифференцированного назначения гепаринов больным с острым коронарным синдромом без подъема сегмента st

Also Published As

Publication number Publication date
RU2542455C2 (ru) 2015-02-20
CA2766533A1 (en) 2011-02-03
RU2012107483A (ru) 2013-09-10
US9492437B2 (en) 2016-11-15
ECSP12011627A (es) 2012-02-29
CR20110674A (es) 2012-04-17
CN102470128A (zh) 2012-05-23
CL2012000196A1 (es) 2012-10-05
US20120238605A1 (en) 2012-09-20
TWI463982B (zh) 2014-12-11
EP2459193A1 (en) 2012-06-06
WO2011012527A1 (en) 2011-02-03
KR20120038982A (ko) 2012-04-24
PE20121401A1 (es) 2012-10-25
UY32807A (es) 2011-02-28
SG177772A1 (en) 2012-03-29
NZ597957A (en) 2014-05-30
AR077427A1 (es) 2011-08-24
JP2013500298A (ja) 2013-01-07
MX2012000457A (es) 2012-01-27
NI201200008A (es) 2012-05-29
AU2010277725B2 (en) 2016-08-18
TW201119655A (en) 2011-06-16
IL217612A (en) 2014-08-31
DOP2012000012A (es) 2012-02-15
CO6491041A2 (es) 2012-07-31
MA33455B1 (fr) 2012-07-03
AU2010277725A1 (en) 2012-02-16

Similar Documents

Publication Publication Date Title
HK1217293A1 (zh) 預防或治療心力衰竭的方法
EP2496299A4 (en) MULTILAYER FIBER-DEVICE FOR THE TREATMENT OF VASCULAR DEFECTS
BR112012025961A2 (pt) composição farmacêutica oral, forma de dosagem de undecanoato de testosterona e método de tratar deficiência de testosterona ou seus sintomas
FR2948016B1 (fr) Orthese pour le traitement de la rhizarthrose
FI20095836A (fi) Probioottinen valmiste koirien maha- ja suolistohäiriöiden ennaltaehkäisyyn tai hoitoon
BRPI1012116A2 (pt) composição farmacêutica para o tratamento de doenças cardíacas
BRPI1008023A2 (pt) forma de dosagem sólida
HK1171168A1 (zh) 利用拉喹莫德治療克羅恩病
PL2115477T3 (pl) Zastosowanie IGFBP-7 do oceny niewydolności serca
DK2319462T3 (da) Protese med komposit komponent
DK3033984T3 (da) Håndholdt gulvbehandlingsapparat
DK2316383T3 (da) Protese med overflader med forskellige texturer
UY33094A (es) Procedimiento para la preparacion de dronedarona
ZA201204521B (en) Beta-cell replication promoting compounds and methods of the their use
BR112012002571A2 (pt) tratamento de minérios de titânio
IL218971A0 (en) Sulfoxide derivatives for the treatment of tumours
GB0700972D0 (en) Treatment of inflammatory disease
BR112013014811A2 (pt) composição de tratamento de pano
EP2440216A4 (en) USE OF A COMPOSITION FOR TREATING MUCOSITIS
BR112013014915A2 (pt) composição curativa e métodos de tratamento
BR112012001900A2 (pt) otamixabano para tratamento de pacientes idosos com insuficiência renal e infarto do miocárdio sem elevação do st
GB0720976D0 (en) Treatment of inflammatory disease
BR112013003275A2 (pt) composição de tratamento oral
BRPI1009322A2 (pt) dose de ave5026 para o tratamento de tromboembolia venosa em pacientes com deficiência renal grave
IL205675A0 (en) Oxazolidinones for the treatment and/or prophylaxis of heart failure

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2471 DE 15-05-2018 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.